Safety and immunogenicity of the Rift Valley fever arMP-12 ΔNSm21/384 candidate vaccine in pregnant ewes

Boumart, Zineb; Bamouh, Zahra; Hamdi, Jihane; Safini, Najete; Tadlaoui, Khalid Omari; Bettinger, George E.; Watts, Douglas M.; Elharrak, Mehdi

doi:10.1016/j.jvacx.2020.100070

Cited by 7 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunogenicity and protective efficacy of arMP12-∆NSm21/384 were found to be equivalent to those of the original MP-12 vaccine in pregnant ewes, lambs, and calves 98 – 100 . arMP12-∆NSm21/384 (1 × 10 5 TCID 50 ) did not cause any fetal malformation in ewes vaccinated at 43 to 150 gestation days, while three out of 17 (18%) ewes vaccinated at 7 to 34 gestation days had fetal malformations in the tail or forelimb, although RVFV RNA was not detected in the affected lambs 101 . Thus, further validation of the vaccine safety of the arMP12-∆NSm21/384 candidate vaccine in pregnant animals is required to determine its suitability for use in livestock ruminants.…”

Section: Next-generation Mp-12 Vaccines: Armp12-∆nsm21/384 Rvax-1 or ...mentioning

confidence: 95%

Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates

Alkan,

Jurado-Cobena,

Ikegami

2023

npj Vaccines

View full text Add to dashboard Cite

Rift Valley fever (RVF) is a zoonotic viral disease transmitted by mosquitoes and causes abortion storms, fetal malformations, and newborn animal deaths in livestock ruminants. In humans, RVF can manifest as hemorrhagic fever, encephalitis, or retinitis. Outbreaks of RVF have been occurring in Africa since the early 20th century and continue to pose a threat to both humans and animals in various regions such as Africa, Madagascar, the Comoros, Saudi Arabia, and Yemen. The development of RVF vaccines is crucial in preventing mortality and morbidity and reducing the spread of the virus. While several veterinary vaccines have been licensed in endemic countries, there are currently no licensed RVF vaccines for human use. This review provides an overview of the existing RVF vaccines, as well as potential candidates for future studies on RVF vaccine development, including next-generation vaccines that show promise in combating the disease in both humans and animals.

show abstract

Section: Next-generation Mp-12 Vaccines: Armp12-∆nsm21/384 Rvax-1 or ...mentioning

confidence: 95%

Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates

Alkan,

Jurado-Cobena,

Ikegami

2023

npj Vaccines

View full text Add to dashboard Cite

show abstract

“…Two MP-12 variants referred to as arMP-12ΔNSs16/198 and arMP-12ΔNSm21/384, which lack an intact NSs and P78/NSm gene, respectively, could induce protective immunity in 3 to 4-month-old young sheep, 4 to 6-month-old cattle, or pregnant ewes without safety concerns [ 55 , 56 , 57 ]. Notably, the neutralizing antibody responses following inoculation with arMP-12ΔNSm21/384 were stronger compared to those induced by arMP-12ΔNSs16/198 [ 58 ]. A large-scale follow-up experiment with 17 pregnant African domestic sheep vaccinated with arMP-12ΔNSm21/384 during the early stage of pregnancy (<35 days gestation) resulted in fetal malformations (forelimb malformation and deformed tail) in 18% of vaccinated ewes [ 58 ].…”

Section: Current Status Of Next-generation Live-attenuated Rvf Vaccin...mentioning

confidence: 99%

“…Notably, the neutralizing antibody responses following inoculation with arMP-12ΔNSm21/384 were stronger compared to those induced by arMP-12ΔNSs16/198 [ 58 ]. A large-scale follow-up experiment with 17 pregnant African domestic sheep vaccinated with arMP-12ΔNSm21/384 during the early stage of pregnancy (<35 days gestation) resulted in fetal malformations (forelimb malformation and deformed tail) in 18% of vaccinated ewes [ 58 ]. At post-mortem, the tissues of dead lambs (spleen, lung, brain, and long bone) were negative for RVFV as analyzed by PCR.…”

Section: Current Status Of Next-generation Live-attenuated Rvf Vaccin...mentioning

confidence: 99%

Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use

et al. 2023

View full text Add to dashboard Cite

Live-attenuated Rift Valley fever (RVF) vaccines transiently replicate in the vaccinated host, thereby effectively initiating an innate and adaptive immune response. Rift Valley fever virus (RVFV)-specific neutralizing antibodies are considered the main correlate of protection. Vaccination with classical live-attenuated RVF vaccines during gestation in livestock has been associated with fetal malformations, stillbirths, and fetal demise. Facilitated by an increased understanding of the RVFV infection and replication cycle and availability of reverse genetics systems, novel rationally-designed live-attenuated candidate RVF vaccines with improved safety profiles have been developed. Several of these experimental vaccines are currently advancing beyond the proof-of-concept phase and are being evaluated for application in both animals and humans. We here provide perspectives on some of these next-generation live-attenuated RVF vaccines and highlight the opportunities and challenges of these approaches to improve global health.

show abstract

“…In the absence of widespread vector control, which may not be feasible given the wide distribution of mosquitoes, vaccination may be the best mitigation strategy. There has been active research in investigating potential vaccines for human and animal use, with the main focus being an eff ective vaccine that prevents the severe forms of disease while avoiding negative side eff ects [4,36,37]. It is also important that the vaccine should be stable and ideally should tolerate being stored and used in resource-limited regions where environmental factors may vary.…”

Section: Introductionmentioning

confidence: 99%

Rift Valley Fever, an Emerging Viral Zoonosis Worthy of Increased Attention

van den Hurk,

Velayudhan*

2024

J Biomed Res Environ Sci

View full text Add to dashboard Cite

Rift Valley Fever (RVF) is an emerging zoonotic disease transmitted by mosquitoes. Though North America is considered free of RVF, surveillance and monitoring of high-risk groups would be important for early detection of potential introduction of the disease. Rift Valley Fever Virus (RVFV) is an RNA virus that primarily affects livestock but can also infect humans with varying severity of infection. Though the disease is mainly prevalent in African countries, the vectors involved in the transmission of RVF are present in many regions in the American and European continents. So, the potential for emergence of this disease in new geographical locations is imminent. There is an unmet need for development of improved research and diagnostic tools to further investigate and manage RVF and to better understand its significance from a One Health perspective.

show abstract

Safety and immunogenicity of the Rift Valley fever arMP-12 ΔNSm21/384 candidate vaccine in pregnant ewes

Cited by 7 publications

References 23 publications

Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates

Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates

Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use

Rift Valley Fever, an Emerging Viral Zoonosis Worthy of Increased Attention

Contact Info

Product

Resources

About